Volume 19, Number 12—December 2013
Dispatch
Novel Variants of Clade 2.3.4 Highly Pathogenic Avian Influenza A(H5N1) Viruses, China
Table 1
Results of HI assays using Re-5 and k0602 antiserum for 7 avian influenza A(H5N1) viruses isolated in China, 2009–2012*
Isolate | Isolation date | Antibody titer, log2 |
|
---|---|---|---|
Re-5 | k0602 | ||
A/chicken/Jiangsu/WJ/2009(H5N1) | 2009 Dec | 4 | 8 |
A/chicken/Jiangsu/XZ/2010(H5N1) | 2010 Mar | 4 | 8 |
A/chicken/northern China/k0602/2010(H5N1) | 2010 May | 4 | 10 |
A/chicken/Shandong/k0603/2010(H5N1) | 2010 Jun | 4 | 10 |
A/chicken/eastern China/ZG56/2011(H5N1) | 2011 Dec | 4 | 5 |
A/chicken/eastern China/JX/2011(H5N1) | 2011 Dec | 3 | 7 |
A/chicken/eastern China/AH/2012(H5N1) | 2012 Sep | 4 | 1 |
Re-5 diagnostic antigen† | NA | 10 | 4 |
*Re-5 and k0602 antiserum were generated by vaccinating specific-pathogen free chickens with the commercial Re-5 vaccine (Qingdao Yebio Bioengineering Co., Ltd, Qingdao, China) and the oil-emulsified inactivated A/chicken/northern China/k0602/2010(H5N1) vaccine, respectively. HI titers against the homologous antigen/virus are shown in boldface. HI, hemagglutination inhibition; NA, not applicable.
†Qingdao Yebio Bioengineering Co., Ltd, China.